Market Size of Human Reproductive Technologies Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 2.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Human Reproductive Technologies Market Analysis
The global human reproductive technologies market is anticipated to grow with a CAGR of nearly 2% during the forecast period. Rising prevalence of infertility and delayed family planning is expected to trigger the market growth. As per the US Department of Health & Human Services, one out of 100 couples are facing problem in conceiving, leading to the adoption of reproductive technologies to treat infertility rate which is further triggering the market growth. Moreover, change in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking is leading to increasing infertility rates and is providing a significant boost to the market. Growing patient awareness regarding the available technologies for treating problems related to reproduction is projected to increase the adoption of human reproductive technologies. However, Limited Insurance Coverage may restrain the growth of the market.
Human Reproductive Technologies Industry Segmentation
As per the scope of the report, Human reproductive technologies involves all current and anticipated uses of technology in reproduction, including infertility treatments, contraceptives drugs and devices. These technologies deals with treating the infertility problems and conceiving.
| By Reproductive Technology | |||||||||||||||
| |||||||||||||||
|
| By Gender | |
| Male | |
| Female |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Human Reproductive Technologies Market Size Summary
The human reproductive technologies market is poised for growth, driven by the increasing prevalence of infertility and delayed family planning. Factors such as lifestyle changes, including delayed childbirth, contraceptive use, and increased alcohol consumption and smoking, are contributing to rising infertility rates, thereby boosting the market. Additionally, heightened awareness among patients about available reproductive technologies is expected to further drive adoption. However, the market's growth may be hindered by limited insurance coverage. The contraceptive segment is anticipated to dominate the market due to the ease of access and administration of oral contraceptive drugs, alongside rising incidences of sexually transmitted diseases and unplanned pregnancies, as well as supportive government initiatives.
Regionally, North America leads the market, benefiting from high obesity rates, delayed conception ages, and lifestyle changes that have increased infertility rates. The region's growth is further supported by easy access to quality healthcare and favorable reimbursement policies. Meanwhile, the Asia Pacific region is expected to experience the fastest growth, fueled by its large population, increasing awareness of reproductive technologies, and the rapid adoption of Western lifestyles. The market is characterized by fragmentation, with several major players like CooperSurgical, Inc., Teva Pharmaceutical Industries, AbbVie Inc., Ferring B.V., and Merck KGaA holding significant market shares.
Human Reproductive Technologies Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Infertility
-
1.2.2 Delayed Family Planning
-
-
1.3 Market Restraints
-
1.3.1 Limited Insurance Coverage
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Reproductive Technology
-
2.1.1 Infertility Treatment
-
2.1.1.1 Drugs
-
2.1.1.1.1 Follitropin Alfa
-
2.1.1.1.2 Follitropin Beta
-
2.1.1.1.3 Menotropins
-
2.1.1.1.4 Others
-
-
2.1.1.2 Devices
-
2.1.1.2.1 Sperm Separation Devices
-
2.1.1.2.2 Sperm Analyzer Systems
-
2.1.1.2.3 Ovum Aspiration Pumps
-
2.1.1.2.4 Micromanipulator Systems
-
2.1.1.2.5 Others
-
-
-
2.1.2 Contraceptive
-
2.1.2.1 Drugs
-
2.1.2.1.1 Oral Contraceptives
-
2.1.2.1.2 Topical Contraceptives
-
2.1.2.1.3 Contraceptive Injectable
-
-
2.1.2.2 Devices
-
2.1.2.2.1 Condoms
-
2.1.2.2.2 IUD
-
2.1.2.2.3 Cervical Caps
-
2.1.2.2.4 Diaphragms
-
2.1.2.2.5 Others
-
-
-
-
2.2 By Gender
-
2.2.1 Male
-
2.2.2 Female
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Human Reproductive Technologies Market Size FAQs
What is the current Human Reproductive Technologies Market size?
The Human Reproductive Technologies Market is projected to register a CAGR of 2% during the forecast period (2024-2029)
Who are the key players in Human Reproductive Technologies Market?
CooperSurgical, Teva Pharmaceutical Industries, AbbVie Inc., Ferring B.V and Merck KGaA are the major companies operating in the Human Reproductive Technologies Market.
